Manage or Perish? pp 469-474 | Cite as
Manage or Perish, Or Choosing to Live without Neuroleptic Drugs
Abstract
Nowadays psychiatrists are discussing if restrictions on so-called care provisions and their excessive regulation may allow for the greatest improvement in the condition of the “users”. Will the postulated quality of treatment deteriorate if economic factors are given even more weight? Or will that concept, which is called “Managed Care”, lead to a discussion of cost-effectiveness and demands for ethics1 which would diminish the use of ineffective treatment in psychiatry and bring the “user” into a position to consciously choose among—perhaps—available types of services? Not only psychiatrists should become involved in the processes related to the introduction of “Managed Care”. If the “users” became involved too, they should have a choice of accepting or refusing special psychiatrists’ offers of treatment. Having a real choice implies knowing the risks and the possibilities of coming off psychiatric drugs.
Keywords
Withdrawal Symptom Psychoactive Drug Neuroleptic Malignant Syndrome Neuroleptic Drug Atypical NeurolepticPreview
Unable to display preview. Download preview PDF.
References
- 1.P. Lehmann, 1999, Forum—the Declaration of Madrid and current psychiatric practice: users’ and advocates’ views, Curr Opin Psychiat (January, in print).Google Scholar
- 2.V. Lehtinen, E. Riikonen, and E. Lahtinen, 1997, Promotion of mental health on the European agenda, Stakes, Helsinki.Google Scholar
- 3.P.L. Gilbert, M.J. Harris, L.A. McAdams, and D.V. Jeste,1995, Neuroleptic withdrawal in schizophrenic patients: a review of the literature, Arch Gen Psychiat 52:173–188.PubMedCrossRefGoogle Scholar
- 4.B. Woggon, 1979, Neuroleptika-Absetzversuche bei chronisch schizophrenen Patienten: 1. Literaturzusammenfassung, Internat Pharmacopsych 14:34–56.Google Scholar
- 5.Dr. Caligari’s psychiatric drugs, 1984, Network Against Psychiatric Assault, Berkeley.Google Scholar
- 6.P. Lehmann, 1996, Schoene neue Psychiatrie, Vol. 1: Wie Chemie und Strom auf Geist und Psyche wirken, Antipsychiatrieverlag, Berlin.Google Scholar
- 7.P Lehmann, 1996, Schoene neue Psychiatrie, Vol. 2: Wie Psychopharmaka den Koerper veraendern, Antipsychiatrieverlag, Berlin.Google Scholar
- 8.B. Ekblom, K. Eriksson, and L.H. Lindstroem, 1984, Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal, Psychopharmacol 83:293–294.CrossRefGoogle Scholar
- 9.R. Degkwitz, and O. Luxenburger, 1965, Das terminale extrapyramidale Insuffizienz-bzw. Defektsyndrom infolge chronischer Anwendung von Neurolepticis, Nervenarzt 36:173–175.Google Scholar
- 10.G.W. Brooks, 1959, Withdrawal from neuroleptic drugs, Am J Psychiat 115:931–932.PubMedGoogle Scholar
- 11.A. Ochsenknecht, 1993, Die seelische Balance—Pflanzenheilkundliche Unterstuetzung bei psychischen Problemen und beim Entzug von Psychopharmaka, in: Statt Psychiatrie (K. Kempker, and P. Lehmann, eds.), pp. 82–94, Antipsychiatrieverlag, Berlin.Google Scholar
- 12.P. Lehmann (ed.), 1998, Psychopharmaka absetzen—Erfolgreiches Absetzen von Neuroleptika Antidepressiva Lithium Carbamazepin und Tranquilizern, Antipsychiatrieverlag, Berlin.Google Scholar
- 13.K. Kempker, 1998, Erfolg in Zahlen?, in: Flucht in die Wirklichkeit Das Berliner Weglaufhaus (K. Kempker, ed.), pp. 270–279, Antipsychiatrievcrlag, Berlin.Google Scholar
- 14.K.B. Jensen, 1998, Entgiftung—im großen wie im kleinen. Für eine Kultur des Respekts, in: Psychopharmaka absetzen—Erfolgreiches Absetzen von Neuroleptika Antidepressiva Lithium Carbamazepin und Tranquilizern (P. Lehmann, ed.), pp. 337–344, Antipsychiatrieverlag, Berlin.Google Scholar